DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,739,074 | -41.4% | 423,610 | -16.2% | 0.03% | -41.3% |
| Q2 2023 | $14,908,865 | +275.1% | 505,214 | +253.5% | 0.05% | +228.6% |
| Q4 2022 | $3,974,855 | +276.1% | 142,929 | +315.2% | 0.01% | +180.0% |
| Q3 2022 | $1,057,000 | +146.4% | 34,421 | +530.0% | 0.01% | +150.0% |
| Q2 2021 | $429,000 | -87.2% | 5,464 | -90.7% | 0.00% | -86.7% |
| Q1 2021 | $3,342,000 | -60.0% | 58,525 | -41.3% | 0.02% | -59.5% |
| Q4 2020 | $8,346,000 | +53.8% | 99,642 | -34.2% | 0.04% | +76.2% |
| Q3 2020 | $5,427,000 | +2280.3% | 151,456 | +1344.1% | 0.02% | +2000.0% |
| Q3 2018 | $228,000 | – | 10,488 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |